Tevogen Bio Holdings enters the back half of May with a pronounced split: the stock is up 33% over the past month, yet it dropped 15.6% in a single session on May 15. That violent reversal — coinciding with the company's latest earnings announcement — frames the week's central tension.
Short sellers have grown more confident in the rally's frailty. SI % FF has climbed from roughly 9.0% in mid-March to 10.4% today, a steady seven-week rebuild that adds weight to the bearish case. The 7% week-on-week rise in shares short marks the sharpest single-week increase in that stretch. Days to cover is a notable 7.9, meaning the position takes more than a week and a half of average volume to unwind — not the kind of reading that implies a quick retreat by bears.
The borrow market tells a more cautious story for new shorts. Cost to borrow has been running near 19% annualised — up 26% from a month ago, even after easing slightly from a mid-week peak above 21%. Availability at just over 51% of estimated short interest means there are roughly equal amounts of lendable shares versus shares already borrowed. That's a tight pool. The 52-week availability floor hit zero — every share was lent out at the most stressed point this year — so while conditions have eased from that extreme, there is no easy room for a large new short position to build without pushing borrow costs higher. The ORTEX short score is 72.5, a level it has held consistently for the past two weeks, suggesting a structurally bearish setup rather than a fresh momentum swing.
The ownership picture is dominated by insiders. CEO Ryan Saadi controls nearly 60% of shares and has not changed his stake since January. The only notable insider activity in the record is a CSO Flomenberg selling small tranches in March — individually immaterial, but consistently directional. On the institutional side, Goldman Sachs added 52,297 shares in Q1, and SEI added 88,448, both near-complete new positions. Vanguard also added, taking its holding from just over 6,000 to 22,674 shares. These are passive and quantitative buyers in a micro-cap; their entry reflects index or model rebalancing rather than fundamental conviction. With a market cap below $35 million and the float tightly held by founders, any institutional move has outsized influence on price.
The earnings history adds context to Thursday's session. At the April 10 print, the stock fell 4.8% on the day but surged 25.9% over the following five sessions — a pattern of initial disappointment followed by recovery. The March 31 event showed a similar dynamic: up 4.4% on the day, then 16% over the week. The February print saw just a 1.3% next-day move. In each case the five-day window proved far more directional than the immediate reaction, which makes the 15.6% single-session fall from the May 15 release worth watching over coming days — the stock closed at $7.95 that Thursday, but small-cap biotech prints here have often resolved later in the week rather than immediately.
Close peers VCEL and ANIX fell 1.3% and 6.0% respectively over the same week, while PSTV slid 14.2% and ACTU dropped more than 20%. The weakness is not isolated to TVGN — small biotech broadly had a rough five sessions — but the magnitude of Thursday's single-day drop still stands out against that peer backdrop. The five-day post-earnings window, and whether borrow costs tighten further as short interest approaches a multi-month high, are the things to watch closely next.
See the live data behind this article on ORTEX.
Open TVGN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
